This paper is marked retracted in the scholarly record (OpenAlex). Interpret its findings with caution.
Retraction Note: Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway
Peng Xu, Handong Wang, Hao Pan, Jiakai Chen, Chulei Deng
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsLung Cancer Research Studies · Glioma Diagnosis and Treatment · Brain Metastases and Treatment
Retraction Note:
Cancer Chemotherapy and Pharmacology (2022) 89:183–196
10.1007/s00280-021-04380-5
The Editors-in-Chief have retracted this article.
Following publication, the authors requested a correction to Figure 2 due to overlaps in the raw images. During further checks, the Publisher identified image overlaps in Figure 4 and a mismatch between the ethics approval committee name in the published article and the submitted document.
The Editors-in-Chief therefore, have lost confidence in the results and conclusions of this article.
The authors did not respond to correspondence from the Publisher about this retraction.
Concerns:
- Fig. 2C Migration, A172, 0 µM appears to overlap with A251, 0 µM;
- Fig. 2E, Invasion, U87 0 µM appears to overlap with U251 0 µM;
- Fig. 4G p-STAT3, A172 appears to overlap with Fig. 5F p-STAT3, U251